Dr. Jorge Brothers, M.D.
What this data tells you about Dr. Brothers
Dr. Jorge Brothers is an urology physician in Lubbock, TX, with 19 years in practice. Based on federal Medicare data, Dr. Brothers performed 13,584 Medicare services across 2,294 unique beneficiaries.
Between the years covered by Open Payments, Dr. Brothers received a total of $13,724 from 51 pharmaceutical and/or device companies across 494 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in urology physician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Brothers is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 9,360 | $17 | $47 |
| Infectious disease DNA/RNA test | 985 | $34 | $50 |
| Automated urinalysis | 624 | $2 | $9 |
| Office visit, established patient, complex (40-54 min) | 399 | $120 | $354 |
| Blood draw (venipuncture) | 378 | $8 | $9 |
| PSA test (prostate cancer screening) | 309 | $18 | $70 |
| Office visit, established patient (30-39 min) | 240 | $88 | $262 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 186 | $133 | $1,918 |
| Bladder ultrasound after voiding | 178 | $7 | $54 |
| Drug injection, under skin or into muscle | 126 | $10 | $72 |
| Yeast/candida DNA test | 101 | $34 | $50 |
| Office visit, established patient (20-29 min) | 97 | $60 | $177 |
| Detection test by nucleic acid for vancomycin resistance strep (vre), amplified probe technique | 80 | $34 | $50 |
| Detection test by nucleic acid for staphylococcus aureus, methicillin resistant (mrsa bacteria), amplified probe technique | 80 | $34 | $50 |
| Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique | 73 | $34 | $50 |
| Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique | 73 | $34 | $50 |
| New patient office visit (45-59 min) | 61 | $104 | $404 |
| Ceftriaxone antibiotic injection | 56 | $0 | $20 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 49 | $23 | $92 |
| Diagnostic exam of bladder and urethra using an endoscope | 42 | $184 | $598 |
| Ultrasound scan of pelvic region through rectum | 21 | $64 | $270 |
| Psa (prostate specific antigen) measurement, free | 20 | $18 | $70 |
| New patient office visit, complex (60-74 min) | 20 | $163 | $508 |
| Insertion of temporary bladder tube | 14 | $32 | $159 |
| Biopsy of prostate gland | 12 | $100 | $640 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
Most payments (99%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Brothers is a mixed practice specialist, with above-average Medicare volume (top 7% in TX), and high industry engagement (low-engagement, top 15%), with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Brothers experienced with denosumab injection (prolia/xgeva)?
Does Dr. Brothers receive payments from pharmaceutical companies?
How do Dr. Brothers's costs compare to other urology physicians in Lubbock?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology